SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of
Investors of Repros Therapeutics, Inc. - RPRX
NEW YORK, Oct. 24, 2013
NEW YORK, Oct. 24, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom &
Gross LLP is investigating claims on behalf of investors of Repros
Therapeutics, Inc. ("Repros" or the "Company")(NASDAQ: RPRX). Such investors
are advised to contact Robert S. Willoughby at email@example.com or
888-476-6529, ext. 237.
The investigation concerns whether Repros and certain of its officers and/or
directors have violated Sections 10(b) and 20(a) of the Securities Exchange
Act of 1934. On October 22, 2013, the Company announced that the FDA has
raised concerns about the reliability of some of the Androxal clinical data
collected during the conduct of the phase III studies. The FDA told Repros
"to request a meeting to discuss the adequacy of studies ZA-301 and ZA-302 as
evidence of pivotal efficacy," the company disclosed.
On this news, shares of Repros fell $6.82 per share to more than 28.79% on
intraday trading to a price of $16.87 on October 22, 2013.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida,
is acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm
pioneered the field of securities class actions. Today, more than 70 years
later, the Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of fiduciary duty,
and corporate misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Press spacebar to pause and continue. Press esc to stop.